RxDoctor Payments DataLook up a doctor →

Roy Webb, MD

Hematology & Oncology · Hot Springs, ARNPI 1346227048

Payments from drug & device makers

$452,003in general payments, 2019–2025

Across 973 payments — averaging $464.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$258K
  • Karyopharm Therapeutics Inc.$49K
  • E.r. Squibb & Sons, L.L.C.$46K
  • Genentech, Inc.$42K
  • United Therapeutics Corporation$16K
  • Pharmacyclics LLC, An Abbvie Company$15K
  • plus $25K from 54 others

What the payments were for

  • Food & beverage$13,64299%
  • Education$1621%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)52$258,178
Karyopharm Therapeutics Inc.27$49,405
E.r. Squibb & Sons, L.L.C.28$46,159
Genentech, Inc.12$41,859
United Therapeutics Corporation4$16,034
Pharmacyclics LLC, An Abbvie Company108$15,441
Bristol Myers Squibb55$6,914
Acerta Pharma LLC2$4,125
Regeneron1$2,200
Novartis76$1,118
Pfizer66$908
Merck54$836
GSK36$631
AbbVie25$564
Incyte Corporation25$463
Daiichi Sankyo Inc.21$446
Sanofi22$396
Astellas Pharma US Inc24$386
Johnson & Johnson(2 entities)21$374
Exelixis Inc.22$366
Gilead(2 entities)21$359
Eisai Inc.15$303
Genentech USA, Inc.21$284
Takeda Pharmaceuticals U.S.A., Inc.10$268
Lilly USA, LLC12$255
EMD Serono, Inc.15$251
Amgen(2 entities)15$247
Bayer12$237
Regeneron Healthcare Solutions, Inc.11$214
Array Biopharma Inc11$195
Puma Biotechnology, Inc.10$166
Beigene USA, Inc.10$165
Sumitomo Pharma America, Inc.6$137
Ipsen Biopharmaceuticals, Inc8$127
Seagen Inc.8$125
Pharmacosmos Therapeutics Inc.7$99
Sobi, Inc5$95
Rigel Pharmaceuticals, Inc.6$94
ADC Therapeutics America, Inc.5$94
AMAG Pharmaceuticals, Inc.5$89
Boehringer Ingelheim4$86
Mirati Therapeutics, Inc.5$86
Beone Medicines USA, Inc.3$77
Myovant Sciences Inc.5$73
Morphosys, US Inc.4$72
Spectrum Pharmaceuticals Inc.4$72
Deciphera Pharmaceuticals Inc.4$70
Heron Therapeutics, Inc.3$66
Tesaro, Inc.3$61
Epizyme, Inc.4$58
G1 Therapeutics, Inc.4$51
AVEO Pharmaceuticals, Inc.3$50
Clovis Oncology, Inc.3$47
Agios Pharmaceuticals, Inc.2$40
Adaptive Biotechnologies Corporation2$38
Celltrion USA Inc.2$34
Geron Corporation2$31
Genmab U.S., Inc.2$27
Foundation Medicine, Inc.2$26
UCB, Inc.1$26

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$452,003 in reported general payments places this provider in the 85th percentile of 92 hematology & oncology providers in Arkansas.

See all hematology & oncology providers in Arkansas

Medicare billing

Part B allowed, 2024
$7,681,938
Medicare patients
1,259
Services billed
300,348

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate68$910,421
ImbruvicaIbrutinib27$449,448
RevlimidLenalidomide21$374,577
KisqaliRibociclib Succinate22$329,013
BrukinsaZanubrutinib23$309,077
LenvimaLenvatinib Mesylate12$293,315
Abiraterone Acetate45$131,394
EliquisApixaban55$40,360
ProcritEpoetin Alfa13$34,788
OrgovyxRelugolix12$32,823
Imatinib Mesylate11$2,641
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen73$1,966
Tamoxifen Citrate76$1,576
Ondansetron OdtOndansetron90$1,357
Anagrelide Hcl11$1,016

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationJakafi$463$910,42168 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$15,441$449,44827 claims
Bristol Myers SquibbRevlimid$6,914$374,57721 claims
NovartisKisqali$1,118$329,01322 claims
Beigene USA, Inc.Brukinsa$165$309,07723 claims
Eisai Inc.Lenvima$303$293,31512 claims
PfizerEliquis$908$40,36055 claims
Johnson & JohnsonProcrit$374$34,78813 claims
Sumitomo Pharma America, Inc.Orgovyx$137$32,82312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 92 hematology & oncology providers in Arkansas.

Other hematology & oncology in Hot Springs

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →